Weight Loss Following Liraglutide Therapy in a Patient With Smith-Magenis Syndrome: A Case Report.

This case reviews the use of a Glucagon-Like Peptide-1 Receptor Agonist (GLP1RA) in a young man presenting with excessive hunger and rapid weight gain compounded by an underlying rare form of genetic obesity, Smith-Magenis syndrome. The patient had, prior to presentation, seen an accelerated and persistent weight gain over the last five years despite attempts at portion control and behavior modification. Due to concerns of worsening metabolic disease, including prediabetes, dyslipidemia, and fatty liver disease, we started the patient on daily liraglutide and gradually titrated to the maximum dose over five months. He was able to tolerate the medication without severe gastrointestinal side effects, and alongside lifestyle and behavioral modifications, the patient lost 22.2 kg (49 lbs) over the course of 11 months. To our knowledge, there is only one other published case report documenting the use of GLP1RA therapy in a patient with Smith-Magenis syndrome.